tradingkey.logo

Maravai LifeSciences Holdings Inc

MRVI
查看详细走势图
3.270USD
-0.030-0.91%
收盘 12/26, 16:00美东报价延迟15分钟
473.23M总市值
亏损市盈率 TTM

Maravai LifeSciences Holdings Inc

3.270
-0.030-0.91%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.91%

5天

-4.66%

1月

-10.16%

6月

+32.39%

今年开始到现在

-40.00%

1年

-40.55%

查看详细走势图

操作建议

Maravai LifeSciences Holdings Inc当前公司基本面数据相对健康,增长潜力较大。当前估值合理,在生物技术与医疗研究行业排名115/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价3.86。中期看,股价处于平稳状态。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Maravai LifeSciences Holdings Inc评分

相关信息

行业排名
115 / 404
全市场排名
232 / 4563
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 11 位分析师
买入
评级
3.857
目标均价
+6.85%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Maravai LifeSciences Holdings Inc亮点

亮点风险
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
估值合理
公司最新PE估值-3.90,处于3年历史合理位
机构减仓
最新机构持股128.65M股,环比减少25.67%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值43.80K

Maravai LifeSciences Holdings Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Maravai LifeSciences Holdings Inc简介

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
公司代码MRVI
公司Maravai LifeSciences Holdings Inc
CEOBrust (Bernd)
网址https://www.maravai.com/

常见问题

Maravai LifeSciences Holdings Inc(MRVI)的当前股价是多少?

Maravai LifeSciences Holdings Inc(MRVI)的当前股价是 3.270。

Maravai LifeSciences Holdings Inc的股票代码是什么?

Maravai LifeSciences Holdings Inc的股票代码是MRVI。

Maravai LifeSciences Holdings Inc股票的52周最高点是多少?

Maravai LifeSciences Holdings Inc股票的52周最高点是6.210。

Maravai LifeSciences Holdings Inc股票的52周最低点是多少?

Maravai LifeSciences Holdings Inc股票的52周最低点是1.665。

Maravai LifeSciences Holdings Inc的市值是多少?

Maravai LifeSciences Holdings Inc的市值是473.23M。

Maravai LifeSciences Holdings Inc的净利润是多少?

Maravai LifeSciences Holdings Inc的净利润为-144.85M。

现在Maravai LifeSciences Holdings Inc(MRVI)的股票是买入、持有还是卖出?

根据分析师评级,Maravai LifeSciences Holdings Inc(MRVI)的总体评级为买入,目标价格为3.857。

Maravai LifeSciences Holdings Inc(MRVI)股票的每股收益(EPS TTM)是多少

Maravai LifeSciences Holdings Inc(MRVI)股票的每股收益(EPS TTM)是-0.839。
KeyAI